Genetype for Ovarian Cancer published in European Journal
Filed with ASX · · 2 pages · English
Melbourne, Australia, 09 November 2022: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”,“GTG”),agloballeaderinguidelinedrivengenomics‐basedtestsinhealth,wellnessandserious disease is delighted to announce the publication of a validation study evaluating the performance of the geneType ovarian cancer test. This 10 year prospective cohort study utilizes data from more than 190,000 wo
Genetic Technologies Limited on 6ix
Earlier from Genetic Technologies
- GeneType Outperforms Traditional Risk Assessments
- GTG Building Momentum on Commercial Plans
- Annual Report to Shareholders and Appendix 4E
- Q4 FY22 Results Milestones and Growth
- GeneType Risk Test Implemented in 9 Siles Health Clinics
Later from Genetic Technologies
- AGM Presentation and Chairmans Address
- GeneType Published in PLUS ONE for CVD & Type 2 Diabetes
- Colorectal Cancer Model Presented at ASCOGI Cancer Symposium
- Appendix 4C and Quarterly Business Update December 2022
- GTG to form Strategic Alliance with global leader QIAGEN
Follow Genetic Technologies into a list and get an email when it puts out news.
Follow Genetic Technologies